The clinical relevance of HMGB1 and HMGB2 in the regulation of identified genes was explored in public databases comparing gene expression in PCa patient samples classified as adenocarcinoma or neuroendocrine types. The gene discussed is HMGB1; the disease is posterior cortical atrophy.